iECURE
Maryann Toto is an accomplished regulatory affairs professional with extensive experience in the biopharmaceutical sector. Currently serving as Vice President of Regulatory Affairs at iECURE, inc. since February 2023, Maryann has held prominent positions including Global Head of Regulatory and Quality at Celyad Oncology and Senior Director Regulatory Affairs at Passage Bio. Maryann's career includes senior roles at Radius Health, Inc. and Spark Therapeutics, Inc., as well as significant experience at Shire Pharmaceuticals and its predecessor ViroPharma Incorporated. Maryann began a career in regulatory affairs at AstraZeneca R&D and worked at Rhone-Poulenc Rorer, following early experience as a cardiac ICU nurse at The Children's Hospital of Philadelphia. Maryann holds a Master of Science in Nursing from the University of Pennsylvania and a Bachelor of Science in Nursing from Jefferson Health.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.